Clinical Trial Update: A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

View source ↗

Summary

A safety study of Empliciti (elotuzumab) in patients with multiple myeloma in Taiwan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Relapsed or Refractory Multiple Myeloma | Status: COMPLETED